DE69608767D1 - Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren - Google Patents

Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren

Info

Publication number
DE69608767D1
DE69608767D1 DE69608767T DE69608767T DE69608767D1 DE 69608767 D1 DE69608767 D1 DE 69608767D1 DE 69608767 T DE69608767 T DE 69608767T DE 69608767 T DE69608767 T DE 69608767T DE 69608767 D1 DE69608767 D1 DE 69608767D1
Authority
DE
Germany
Prior art keywords
production method
formulations containing
benzimidazole compound
new stable
acid labeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69608767T
Other languages
German (de)
English (en)
Inventor
Rodes Montserrat Ballester
Boven Marinus Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8289322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69608767(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69608767D1 publication Critical patent/DE69608767D1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69608767T 1995-02-01 1996-01-26 Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren Revoked DE69608767D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
PCT/ES1996/000013 WO1996023500A1 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion

Publications (1)

Publication Number Publication Date
DE69608767D1 true DE69608767D1 (de) 2000-07-13

Family

ID=8289322

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69608767T Revoked DE69608767D1 (de) 1995-02-01 1996-01-26 Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren
DE29623938U Expired - Lifetime DE29623938U1 (de) 1995-02-01 1996-01-26 Neue stabile galenische Formulierungen, enthaltend eine säureempfindliche Benzimidazolverbindung
DE69634613T Revoked DE69634613T2 (de) 1995-02-01 1996-01-26 Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer Herstellung

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE29623938U Expired - Lifetime DE29623938U1 (de) 1995-02-01 1996-01-26 Neue stabile galenische Formulierungen, enthaltend eine säureempfindliche Benzimidazolverbindung
DE69634613T Revoked DE69634613T2 (de) 1995-02-01 1996-01-26 Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer Herstellung

Country Status (20)

Country Link
US (1) US5626875A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0773025B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4183746B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100331290B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR002702A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE193649T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU4540396A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2184842C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69608767D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK0773025T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2094694B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI121730B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU229219B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL116673A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN186596B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT773025E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI0993830T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW503115B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996023500A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA96683B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DE69634160T2 (de) 1995-09-21 2005-12-22 Pharma Pass Ii Llc, Irvine Ein säurelabile Omeprazol enthaltende Arzneizusammensetzung und Verfahren zu deren Herstellung
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
FR2774288B1 (fr) † 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
CN1141097C (zh) * 1998-04-20 2004-03-10 卫材株式会社 含有稳定化的苯并咪唑类化合物的组合物
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
EP1105105B1 (en) * 1998-08-12 2006-03-29 ALTANA Pharma AG Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US7220762B1 (en) 1999-10-20 2007-05-22 Eisai R&D Management Co., Ltd. Methods for stabilizing benzimidazole compounds
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2244167T3 (es) * 1999-12-16 2005-12-01 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Nuevas preparaciones farmaceuticas multiunitarias estables que contienen bencimidazoles sustituidos.
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
KR20030051794A (ko) * 2000-11-10 2003-06-25 에프. 호프만-라 로슈 아게 가수분해에 불안정한 조성물
EP1404323B1 (en) * 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
EE05402B1 (et) 2001-07-16 2011-04-15 Janssen Pharmaceutica N.V. Meetod bensimidasooli-tüüpi ühendite valmistamiseks ning k?rvalsaadusena moodustunud sulfoonide eemaldamiseks
US20040062804A1 (en) * 2001-09-28 2004-04-01 Der-Yang Lee Modified release dosage forms
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
ES2299710T3 (es) * 2002-08-02 2008-06-01 Ratiopharm Gmbh Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
CA2521379C (en) * 2003-04-08 2013-07-02 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
RU2005134364A (ru) * 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
AU2003245033A1 (en) * 2003-05-08 2004-11-26 Podili Khadgapathi An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
AU2003272086A1 (en) * 2003-10-14 2005-04-27 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
WO2005107721A2 (en) 2004-05-07 2005-11-17 Altana Pharma Ag Pharmaceutical dosage form comprising pellets as well as its manufacturing process
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP1830822A1 (en) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
AU2006213439A1 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1785135A1 (en) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
WO2007075980A2 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
WO2008012621A2 (en) * 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
DK2565195T3 (en) 2007-03-29 2015-06-29 Wyeth Llc PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
AU2008233129B2 (en) 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
US20110150945A1 (en) * 2008-08-11 2011-06-23 Mepha Gmbh Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20140255503A1 (en) * 2011-11-02 2014-09-11 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical composition of omeprazole
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
JP6686013B2 (ja) 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829055A (en) * 1958-02-07 1960-02-24 Charles E Frosst And Company Improvements in or relating to pharmaceutical preparations
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS58208155A (ja) * 1982-05-28 1983-12-03 Sumitomo Electric Ind Ltd 光伝送用ガラスフアイバの製造方法
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
IT1241740B (it) * 1990-06-22 1994-02-01 Edi Bondioli Protezione per una forcella di estremita' di un albero cardanico
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
ES2238796T3 (es) 2005-09-01
ATE193649T1 (de) 2000-06-15
TW503115B (en) 2002-09-21
ES2094694A1 (es) 1997-01-16
JP4183746B2 (ja) 2008-11-19
DE69634613T2 (de) 2006-03-09
ES2094694B1 (es) 1997-12-16
FI121730B (fi) 2011-03-31
DK0773025T3 (da) 2000-10-09
EP0773025A1 (en) 1997-05-14
CA2184842A1 (en) 1996-08-08
IL116673A0 (en) 1996-05-14
FI963916A0 (fi) 1996-09-30
EP0773025B1 (en) 2000-06-07
HU229219B1 (en) 2013-09-30
HUP9603014A3 (en) 2000-12-28
IL116673A (en) 2000-10-31
SI0773025T1 (en) 2000-10-31
SI0993830T1 (en) 2005-10-31
CA2184842C (en) 2007-08-07
FI963916L (fi) 1996-09-30
EP0993830A3 (en) 2001-10-04
US5626875A (en) 1997-05-06
PT773025E (pt) 2000-10-31
ES2148725T3 (es) 2000-10-16
EP0993830B1 (en) 2005-04-13
AR002702A1 (es) 1998-04-29
JPH09511257A (ja) 1997-11-11
DK0993830T3 (da) 2005-08-08
WO1996023500A1 (es) 1996-08-08
PT993830E (pt) 2005-06-30
EP0993830A2 (en) 2000-04-19
HUP9603014A2 (hu) 1998-03-30
ATE292967T1 (de) 2005-04-15
DE29623938U1 (de) 2000-10-05
AU4540396A (en) 1996-08-21
KR100331290B1 (ko) 2002-11-22
DE69634613D1 (de) 2005-05-19
IN186596B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-10-06
ZA96683B (en) 1997-09-23

Similar Documents

Publication Publication Date Title
DE69608767D1 (de) Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren
DE59807213D1 (de) 11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
DE69707650D1 (de) Reinigungsmittel die xanthangummi und vernetzte polyacylsäure enthalten
ATA902196A (de) Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung
ITMI991860A0 (it) Derivati di acidi 2-ammino-biciclo(3.1.0)-esan-2,6-bicarbossilici e pr ocedimento per la loro preparazione
FI962917A7 (fi) Mikrokapselit, menetelmä niiden valmistamiseksi, ja niiden käyttö
ATE151764T1 (de) Neue benzopyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltenden zubereitungen
FI930387A7 (fi) Stabiili hoitoshampoo, joka sisältää rasvahappoa
GB2309695B (en) Asiatic acid derivative, it's manufacturing method and dermatological agent containing it
DE59007528D1 (de) Biskationische säureamid- und -imidderivate und verfahren zu ihrer herstellung.
IT1293968B1 (it) Produzione ed utilizzo di composizioni comprendenti alte concentrazioni di attivita' di vitamina b12.
DE68920571D1 (de) Halbleiterlaser-Vorrichtung und Verfahren zu ihrer Herstellung.
DE59814132D1 (de) Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
IT8848259A0 (it) 1,4-diidropiridine, loro procedimento di preparazione e loro applicazione come medicamenti
FR2763949B1 (fr) Compose stabilisant, composition le contenant et procede l'utilisant
FI961521L (fi) Lääkeformulaatioiden valmistusmenetelmä
IT1285009B1 (it) Procedimento ed apparecchiatura perfezionati per la fabbricazione di maniche.
FI951053A7 (fi) Nanohiukkasia, jotka sisältävät vaikuttavaa ainetta ja polyketaaliviinihappoamidia, menetelmä niiden valmistamiseksi ja niiden käyttö
IT8720260A0 (it) Derivati di 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro applicazione come medicamenti.
ATE194616T1 (de) Substituierte 4-phenyl-thiazole derivate, verfahren zu deren herstellung und pharmazeutische zusammenstellungen die sie enthalten
DE69818516D1 (de) Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
DE69738570D1 (de) Konzentrierte wässerige tensidzusammensetzungen von betaintyp und verfahren zu deren herstellung
ATE289595T1 (de) Neue pyrimidin-2,4,6-trion-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten
DE69931038D1 (de) Neue polysaccharidderivate, verfahren zu ihrer herstellung und medizinische zusammensetzungen die diese als aktives bestandteil enthalten
DE59300649D1 (de) Stabilisierte Percarbonsäurelösungen und Verfahren zu deren Herstellung.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation